Whole exome sequencing for noncancer indications

Record ID 32013000831
English
Authors' recomendations: In the past decade, technologies that conduct rapid sequencing of DNA segments have been providing detailed information on genetic variants. Massively parallel sequencing is allowing generation of data across the entire genome (the complete set of genetic information contained in any given cell of an organism). Whole exome sequencing (WES) involves sequencing all of the protein-coding regions (called exons) of an individual's genes (known as the exome). While exons represent only 1% of the genome, they account for approximately 85% of disease-causing variants. Through identification of variants across the exome, WES avoids the need to run multiple single-gene tests, which require prior information about variants that may be causing a disease or condition. WES has been performed in a wide variety of disorders, including Mendelian (caused by variants in a single gene) and multifactorial (affected by variants in many genes as well as environmental factors) disorders to identify de novo variants (i.e., new genetic variants in the tested individual) or inherited variants. A majority of WES studies have been conducted for rare conditions with Mendelian inheritance patterns, whereby a single gene affects the condition and a variant is usually rare with a large effect. On the other hand, analysis of multifactorial disorders (whereby variants in many genes generally each have small effects) has been conducted in some neurological disorders, but is limited for other conditions. WES has primarily been used for 2 purposes—discovery and diagnosis. Discovery refers to identification of novel or previously identified variants that may have a protein-altering function on the disease being studied. In addition, WES has generally been used as a diagnostic tool in individual cases. Identification of protein-altering (and possibly deleterious) variants using WES may provide information on potential new avenues for diagnosis and treatment.
Details
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Exome
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: 2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.